Rational Design of Highly Potent, Selective, and Bioavailable SGK1 Protein Kinase Inhibitors for the Treatment of Osteoarthritis
- 21 December 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (2) , 1567-1584
Abstract
The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. Today, no oral disease-modifying treatments are available and chronic treatment in this indication sets high requirements for the drug selectivity, pharmacokinetic, and safety profile. We describe the identification of a highly selective druglike 1H-pyrazolo[3,4-d]pyrimidine SGK1 inhibitor 17a that matches both safety and pharmacokinetic requirements for oral dosing. Rational compound design was facilitated by a novel hSGK1 co-crystal structure, and multiple ligand-based computer models were applied to guide the chemical optimization of the compound ADMET and selectivity profiles. Compounds were selected for subchronic proof of mechanism studies in the mouse femoral head cartilage explant model, and compound 17a emerged as a druglike SGK1 inhibitor, with a highly optimized profile suitable for oral dosing as a novel, potentially disease-modifying agent for osteoarthritis.Keywords
This publication has 52 references indexed in Scilit:
- Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular RemodelingCirculation, 2012
- Rationally Designing Safer Anilines: The Challenging Case of 4-AminobiphenylsJournal of Medicinal Chemistry, 2012
- Data processing and analysis with theautoPROCtoolboxActa Crystallographica Section D Structural Biology, 2011
- Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase InhibitorsPLOS Computational Biology, 2009
- Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer TherapeuticCancer Research, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Crystal structure of the kinase domain of serum and glucocorticoid‐regulated kinase 1 in complex with AMP–PNPProtein Science, 2007
- Sequential Progression of the Differentiation Program by Bone Morphogenetic Protein-2 in Chondrogenic Cell Line ATDC5Experimental Cell Research, 1998
- Phototoxicity to sulphonamide‐derived oral antidiabetics and diuretics: investigations in hairless micePhotodermatology, Photoimmunology & Photomedicine, 1997
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D Structural Biology, 1994